Intellectual Property Group Co-Leader Imron Aly was quoted on a U.S. Supreme Court patent ruling in Oil States Energy Services LLC v. Greene’s Energy Group LLC that upheld the America Invents Act (AIA) review system for challenging patents as constitutional, with some key operation changes.
Hatch-Waxman and Biosimilars Practice Group Leader Sailesh Patel explained why some biosimilar companies engaged in Biologics Price Competition and Innovation Act (BPCIA) litigation may choose to settle.
Hatch-Waxman and Biosimilars Practice Group Leader Sailesh Patel was featured on the ongoing Biologics Price Competition and Innovation Act (BPCIA) Litigation he is watching.
Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly examines how current Hatch-Waxman legal proceedings can be applied to Biologics Price Competition and Innovation Act (BPCIA) litigation.
Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly forecast the significance of the U.S. Supreme Court ruling in Oil States Energy Services, LLC, v Greene’s Energy Group, LLC, and how it could impact future patent challenge cases.
This Special Report is written by Helen Ji, Schiff Hardin LLP associate, Rekha Hanu, executive director and chief IP counsel at Akorn Pharmaceuticals, and Christine Simmon, SVP for policy and strategic alliances at the Association for Accessible Medicines.
Partner Kevin Nelson was quoted on the Knowledge Ecology International’s urging of the National Institutes of Health (NIH) to leverage the Bayh-Dole Act in order to combat rising drug prices.
Like generic drugs in the 1980s, biosimilars today face a number of regulatory, legal, scientific, and public perception obstacles to continued growth.
This past November, the US Supreme Court heard oral arguments in a case that may dramatically affect how patents covering biologic drugs are litigated: Oil States Energy Services, LLC v Greene’s Energy Group, LLC.
This year brought us very significant changes in patent jurisprudence from the Supreme Court and Federal Circuit affecting Chemical & Life Sciences patent practice.
On July 18, 2017, FDA held a public meeting to address efforts to ensure a balance between innovation in drug development and accelerating the access of the public to lower-cost alternatives to innovator drug therapies is maintained under the Drug Price Competition and Patent Term Restoration Act.
On June 21, the Food and Drug Administration announced a Drug Competition Action Plan in order to attempt to address ways that the agency’s rules have been, in the agency’s view, “gamed” to create obstacles that delay generic drug approvals to reduce generic competition.
This week, the Supreme Court unanimously rejected the Federal Circuit’s broad reading of the patent venue statute for domestic corporations in TC Heartland LLC v. Kraft Foods Group Brands LLC, No. 16-341, 2017 WL 2216934 (U.S. May 22, 2017).
Arent Fox Patent Partner Janine Carlan is a featured speaker at the upcoming American Conference Institute’s Women Leaders in Life Sciences Law Conference.